EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Statin therapy and mortality in critically ill heart failure patients: Insights from a triangulated real-world design study

Li Wang iD, Yibing Wang

PLOS One · 2025

DOI: 10.1371/journal.pone.0334822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift PLOS One, 2025. Verfasst von Li Wang und 1 weiteren Autor:innen. Beteiligte Einrichtung: Second Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Heart Failure, Critical Illness. Die Arbeit nennt 33 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

This study is aimed to evaluate the association between statin therapy and intermediate-term survival in critically ill patients with heart failure (HF). Using a real-world retrospective cohort from the MIMIC-IV database, we assessed all-cause mortality at 90 and 180 days following ICU admission. To reduce confounding factors, we applied a triangulated analytic framework incorporating propensity score matching, inverse probability of treatment weighting and standardized mortality ratio weighting. Survival outcomes were additionally examined across different statin types, including atorvastatin, rosuvastatin, simvastatin and pitavastatin, using stratified Kaplan–Meier analysis. Among over 8,000 eligible patients, statin use during hospitalization was consistently associated with reduced mortality at both time points across all models. Stratified survival curves showed comparable trends among the different statin types. These findings suggest a potential class-wide survival benefit of statin therapy in the ICU setting for HF patients and highlight the need for further studies to determine whether specific statin selection offers additional clinical advantages.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsHeart FailureCritical IllnessHumansMaleFemaleAgedRetrospective StudiesMiddle AgedIntensive Care UnitsKaplan-Meier EstimateAged, 80 and overRosuvastatin CalciumPropensity Score

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsRosuvastatin Calcium

Autor:innen und Institutionen

  • Second Department of Cardiology, The Second Hospital of Hebei Medical University, Shijiazhuang, China.
  • Department of Neurosurgery, Handan Central Hospital, Handan, China.

ORCID-Profile: Li Wang

Zitieren

APA

Wang, L., & Wang, Y. (2025). Statin therapy and mortality in critically ill heart failure patients: Insights from a triangulated real-world design study. PLOS One. https://doi.org/10.1371/journal.pone.0334822

Vancouver

Wang L, Wang Y. Statin therapy and mortality in critically ill heart failure patients: Insights from a triangulated real-world design study. PLOS One. 2025. doi:10.1371/journal.pone.0334822

BibTeX
@article{Wang2025,
  author = {Wang, Li and Wang, Yibing},
  title = {Statin therapy and mortality in critically ill heart failure patients: Insights from a triangulated real-world design study},
  journal = {PLOS One},
  year = {2025},
  doi = {10.1371/journal.pone.0334822}
}
Kostenlos starten →